Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 4NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Classical hematology 1

Conditions

Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Accelerated Phase 1Congenital Abnormalities 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1

Interventions

Cyclophosphamide 4Azacitidine 3venetoclax 2fludarabine phosphate 2fludarabine 2ON 01910 2Mycophenolic Acid 2Melphalan 2Filgrastim 2Cyclosporine 2Busulfan 2lonafarnib 1itacitinib 1ilorasertib 1exatecan 1darinaparsin 1cedazuridine 1Whole-Body Irradiation 1Transplantation 1Teriparatide 1Radiotherapy 1Piperacillin, Tazobactam Drug Combination 1Peripheral Blood Stem Cell Transplantation 1Parathyroid Hormone 1Methotrexate 1Mesna 1INCB039110 1Granulocyte Colony-Stimulating Factor 1Glycopeptides 1Etoposide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Anemia, Refractory, with Excess of Blasts × Transplantation × Clear all
NCT01175785 2019-03-05

Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies

Nohla Therapeutics, Inc.

Phase 2 Completed
15 enrolled
Classical hematologyOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡